Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07283497 · ClinicalTrials.gov registry record · Phase 4
Itraconazole Therapy In Bronchiectasis With Airway Mold
A Phase 4 study of Bronchiectasis and Fungal Infection of Upper Respiratory Tract, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07283497: Recruiting Phase 4 study of Bronchiectasis and Fungal Infection of Upper Respiratory Tract, sponsored by Mayo Clinic.
NCT07283497 is a Phase 4 study of Bronchiectasis and Fungal Infection of Upper Respiratory Tract that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 386-participant average among 13 other Bronchiectasis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07283497, a Phase 4 study of Bronchiectasis and Fungal Infection of Upper Respiratory Tract, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to evaluate the feasibility of itraconazole therapy in patients with bronchiectasis and airway mold. Feasibility will be assessed through recruitment success, treatment adherence, tolerability, and participant retention. The study will also explore the impact on respiratory symptoms and airway microbiome diversity.
Primary Outcome
Recruitment will be measured as the proportion of eligible patients who consent and enroll out of patients screened, reported as a percentage, with a benchmark of \>60%.
Conditions Studied
Interventions
- DRUG Itraconazole 200 mg
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-15 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 4 |
What NCT07283497 shows while recruiting
NCT07283497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 386-participant average among 13 other Bronchiectasis trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Bronchiectasis appearing as the primary indexed condition, and to 1 intervention - of which Itraconazole 200 mg is the first listed.
NCT07283497 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07283497 about?
NCT07283497 is a clinical study titled "Itraconazole Therapy In Bronchiectasis With Airway Mold". The primary objective of this study is to evaluate the feasibility of itraconazole therapy in patients with bronchiectasis and airway mold. Feasibility will be assessed through recruitment success, treatment adherence, tolerability, and participant retention. The study will also explore the impact o...
What is the current status of trial NCT07283497?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2026-03-15. Estimated completion is 2030-12-31.
What conditions does trial NCT07283497 study?
This clinical trial studies the following conditions: Bronchiectasis, Fungal Infection of Upper Respiratory Tract.
What interventions are being tested in trial NCT07283497?
The interventions under investigation include: Itraconazole 200 mg (DRUG).
Who is sponsoring clinical trial NCT07283497?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07283497 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchiectasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07283497's enrollment target sits among peer trials
30 9th of 13 higher than 4 of 13 other Bronchiectasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bronchiectasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hypertonic Saline in NCFB
RECRUITING · Phase 4
-
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
RECRUITING · Phase 3
-
Evaluation Of The Lung Microbiome In NTM Bronchiectasis
RECRUITING
-
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
RECRUITING · NA
-
OLE Therapy With BE Patients in Home Care Study
RECRUITING · NA
-
Natural History of Bronchiectasis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI